Imunon (IMNN) grants CSO 15,736 stock options at $3.95 exercise price

Rhea-AI Filing Summary

Imunon, Inc. reported an equity award to its Chief Scientific Officer, Khursheed Anwer. On January 2, 2026, he received a stock option grant covering 15,736 shares of Imunon common stock. The option has an exercise price of $3.95 per share, which matches the closing price of Imunon common stock on the grant date, and there was no cash paid for receiving the option itself.

The vesting schedule is time-based: half of the options vest on the grant date, with an additional one-quarter vesting on the first anniversary of the grant date and the remaining one-quarter vesting on the second anniversary. All 15,736 options are reported as directly owned following this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Anwer Khursheed

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NJ 08648

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.95(1)	01/02/2026		A		15,736		01/02/2026(2)	01/02/2036	Common Stock	15,736	$0	15,736	D

Explanation of Responses:

1. Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

2. The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

	/s/ Susan Eylward, Attorney-in-Fact for Khursheed Anwer	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who received the stock option grant reported in Imunon (IMNN)'s Form 4?

The grant was made to Khursheed Anwer, who serves as Chief Scientific Officer of Imunon, Inc.

How many stock options were granted to the Imunon (IMNN) Chief Scientific Officer?

The Form 4 reports a grant of 15,736 stock options, each representing the right to buy one share of Imunon common stock.

What is the exercise price of the stock options granted by Imunon (IMNN)?

The options have an exercise price of $3.95 per share, which represents the closing price of Imunon common stock on the grant date.

When do the Imunon (IMNN) stock options granted to the CSO vest?

The options vest as follows: 1/2 on the grant date, 1/4 on the one-year anniversary, and 1/4 on the two-year anniversary of the grant date.

How many derivative securities does the Imunon (IMNN) CSO own after this Form 4 transaction?

Following the reported transaction, the Chief Scientific Officer is shown as directly owning 15,736 stock options.

Was any cash paid to receive the Imunon (IMNN) stock option grant?

No cash was paid for the grant itself; the Form 4 lists the transaction price per option as $0, with an exercise price of $3.95 per share when the option is used.